Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Peter Impey

- PMLiVE

UCB’s Bimzelx granted FDA approval to treat hidradenitis suppurativa in adults

The inflammatory skin disease affects approximately one in every 100 people in the US

- PMLiVE

Is the new Health and Social Care Select Committee a battleground or consensus opportunity?

By Andie Gbedemah

- PMLiVE

Bringing more effective storytelling to medical publications

By Nicole Parker, Kristen Quinn and Stephen Towers

- PMLiVE

Health Awareness V Health Anxiety: Is the increase of online health content a help or hindrance?

Medical Writer, Steph Gathercole, looks at the impact increased access to online health information has on the public through the lens of Anxiety

Mednet

Biogen Idec building

Biogen/Eisai’s Alzheimer’s drug lecanemab receives CHMP recommendation

The neurodegenerative disorder affects an estimated 6.9 million people in Europe

- PMLiVE

The potential of generative AI and its practical application in the world of promotional medical communications

By Markus Vaga and Dave Ferguson

- PMLiVE

Impending ESG regulations present communications opportunity for pharma

By Trey Watkins and Gemma Medcalf

- PMLiVE

Insights and reflections from the Mtech Access transforming healthcare symposium

Our transforming healthcare symposium was held on Tuesday 5th November 2024. In this article, Prof Phil Richardson (Chief Innovation Officer, Mtech Access) shares his reflections from the day.

Petauri Evidence

- PMLiVE

EU Joint Clinical Assessment (JCA) – Implications for Pharma and Medtech

Katie Rose (Consultant – Market Access), Maria Dimitrova (Consultant – HTA) and Samantha Gillard (Director – HTA) provide an overview of the EU Joint Clinical Assessment (JCA) and what it...

Petauri Evidence

- PMLiVE

Movember 2024 – Men’s Health

This Movember, Innovative Trials are raising awareness about men’s health issues like prostate cancer, testicular cancer, and mental health.

Innovative Trials

- PMLiVE

Merck gains rights to LaNova’s PD-1/VEGF bispecific antibody in deal worth over $3.2bn

A phase 1 clinical trial of the candidate in advanced solid tumours is currently enrolling patients

- PMLiVE

European Medicines Group appoints Rippon Ubhi as chair

Ubhi will maintain her role as country lead for Sanofi UK and Ireland

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links